Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1713406

	registered interest
	date	24/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Coronavirus
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what her timetable is for the rollout of Endo Barriers on the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	23480
	answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>The implantation of a duodenal–jejunal bypass liner, also known as an endo barrier, for managing type 2 diabetes, is not recommended by the NICE, and therefore not available on the National Health Service. Current evidence on the safety and efficacy of the device for managing type 2 diabetes is limited in quality and quantity. For this reason, the NICE recommends that the procedure should only be done as part of a research study. Further information on the NICE guidelines is available at the following link:</p><p><a href="https://www.nice.org.uk/guidance/ipg518/chapter/1-Recommendations" target="_blank">https://www.nice.org.uk/guidance/ipg518/chapter/1-Recommendations</a></p><p>The NICE may update the guidance, upon publication of further evidence. The NICE recommends that people with type 2 diabetes receive eight care processes at least annually, to support them to achieve three treatment targets to prevent diabetes related complications. The care processes include checks on blood glucose and body mass index, to support weight management. Delivery of all eight care processes is associated with reduced emergency admissions, amputations, and retinopathy. NHS England commissions two national lifestyle services to support adults with type 2 diabetes to manage their weight and improve their health and wellbeing. These are the NHS Digital Weight Management Programme and the NHS Type 2 Diabetes Path to Remission Programme. The NICE guidance for the care and management for adults with type 2 diabetes is available at the following link:</p><p><a href="https://www.nice.org.uk/guidance/ng28" target="_blank">https://www.nice.org.uk/guidance/ng28</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 30/04/2024 16:33:44 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1712662

	registered interest
	date	22/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Strokes: Depressive Illnesses
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether her Department (a) has taken and (b) plans to take steps to (a) monitor the incidence of depression among stroke survivors and (b) improve interventions to enhance (i) aftercare and (ii) quality of life for those people.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	22946
	answer	answer is ministerial correction date of answer 26/04/2024 answer text <p>Depression affects approximately one third of people with stroke, and stroke services in the National Health Service are very aware of the impact this can have on the quality of life and level of independence of people who experienced a stroke, and the importance of understanding through measurement which people are affected, to support appropriate management.</p><p>The National Clinical Guideline for Stroke 2023 recommends that people with stroke should be routinely screened for anxiety and depression using standardised tools, the results of which should be used alongside other sources of information to inform clinical formulation of treatment and support needs.</p><p>The latest published Sentinel Stroke National Audit Programme (SSNAP) data, from October to December 2023, showed that 92.4% of stroke patients were screened for mood disturbances, including depression, in hospital. 75% of stroke patients who were followed up at six months post stroke also had a mood screen, with 53% of patients receiving the psychological support needed.</p><p>NHS England is driving implementation of the National Service Model for an Integrated Community Stroke Service (ICSS) with a number of specific projects aimed at improving delivery of psychological rehabilitation. The ICSS model is vital to support psychological recovery, return to work, and improved quality of life. From July 2024, the SSNAP will record the amount of psychological rehabilitation provided to patients, and measure changes in quality of life over time.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 26/04/2024 12:17:40 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1712667

	registered interest
	date	22/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) trial and (b) roll-out early cancer screening.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	22951
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>In England, early cancer screening is already in place for cervical, breast, and bowel cancer. The UK National Screening Committee (UK NSC) does not currently recommend screening for prostate cancer due to the inaccuracy of the current best test, called Prostate Specific Antigen. We are providing £16 million of funding to Prostate Cancer UK's £42 million trial, which is aimed at helping us find a way of catching prostate cancer in men as early as possible. The UK NSC is also commissioning evidence for six possible approaches to targeted prostate screening for those at higher risk. The UK NSC will publish its recommendations when complete.</p><p>NHS England is responsible for the running of the Targeted Lung Health Check Programme, and its conversion to a nationally rolled out NHS Targeted Lung Cancer Screening Programme by 2030.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 14:48:02 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1701263

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Semaglutide: Health Hazards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to increase the public's awareness of the side effects that can arise from taking weight loss drugs such as Ozempic.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	21989
	answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) plays a pivotal role in ensuring the safety, efficacy, and quality of medicines and healthcare products available to patients in the United Kingdom. Patient safety remains the MHRA’s highest priority, and they take every opportunity to encourage reporting of any safety concerns to the Yellow Card scheme, which helps to improve the safe use of medicines and medical devices for everyone.</p><p>New medicines including, Mounjaro and Wegovy, are intensively monitored to ensure that any new safety concerns are identified promptly. The Commission on Human Medicines and the MHRA encourages the reporting of all suspected reactions to newer drugs and vaccines, which are denoted by an inverted Black Triangle symbol. This symbol appears next to the name of a relevant product in drug safety updates, the British National Formulary and the Nurse Prescribers’ Formulary, the monthly index of medical specialities, the electronic medicines compendium, and advertising material. Patient information leaflets accompanying licensed medicines in the UK must include a description of the adverse reactions which may occur in normal use of the medicinal product, as well as information on how to report them. All adverse reactions must be reflected in the leaflet, in language that the patient will understand.</p><p>The MHRA has received a small number of reports of falsified and unlicenced medicines being sold illegally online as a treatment for weight loss. The agency has issued public health messaging warning of the dangers of buying such medicines from illegal trading sources online.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/04/2024 11:07:07 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1701335

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Blood Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 7 March 2024 to Question 15636 on Blood Cancer: Drugs, on what date her Department first became aware of challenges presented by the appraisal of combination therapies; and what solutions her Department is considering with NHS England to ensure continued equal access to combination medicines for multiple myeloma across the UK.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	21993
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>NHS England, the National Institute for Health and Care Excellence (NICE), and the Association of the British Pharmaceutical Industry (ABPI) worked closely with the Competition and Markets Authority (CMA) over a number of years on the CMA’s statement on combination therapies, published in November 2023.</p><p>The steps taken by the CMA provide a clear commercial position that means that deals involving multiple drugs licensed by different companies can now be agreed under specific circumstances. This has been welcomed by the ABPI as an opportunity to unlock the door to more transformative combination therapies on the National Health Service.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 15:37:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1701336

	registered interest
	date	16/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Drugs: Procurement
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will have discussions with NHS England on the effectiveness of its Commercial Framework in tackling challenges presented by the appraisal and reimbursement system when applied to combination medicines and medicines with multiple indications.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	21994
	answer	answer is ministerial correction date of answer 24/04/2024 answer text <p>As part of the 2024 voluntary scheme for branded medicines pricing, access, and growth, NHS England has committed to undertake two consultations on its Commercial Framework for New Medicines. The first of these will be launched in summer 2024 and will align with the Competition and Markets Authority’s (CMA) statement on combination medicines. In addition, it will be more explicit about the approach taken for assessing the eligibility of medicines treating multiple indications to qualify for indication specific pricing mechanisms.</p><p>Following the first consultation, a revised framework will be published by the end of 2024, and engagement with pharmaceutical companies and patient groups on these issues is already taking place.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/04/2024 15:42:59 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1697030

	registered interest
	date	19/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Oral Cancer: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of people diagnosed with mouth cancer in the last twelve months.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	19359
	answer	answer is ministerial correction date of answer 27/03/2024 answer text <p>The information requested is not available for the last twelve months. The most recent data available from 2021 shows 9,018 people were diagnosed with mouth cancer in England. Further information is available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/cancer-registration-statistics/england-2021---summary-counts-only" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/cancer-registration-statistics/england-2021---summary-counts-only</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/03/2024 10:13:35 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1694454

	registered interest
	date	07/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what her expected timescale is for the availability of the Galleri blood test in cancer testing and diagnosis across the NHS.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	17545
	answer	answer is ministerial correction date of answer 13/03/2024 answer text <p>The NHS-Galleri trial is looking into the use of a new blood test to see if it can help the National Health Service to detect cancer early, when used alongside existing cancer screening. The trial recruited the target of 140,000 participants, and interim results are expected in spring or summer 2024.</p><p>If the trial is successful, the NHS has committed to rolling out up to one million Galleri tests in 2024 and 2025, as part of an interim implementation pilot. The clinical trial is currently planned to conclude in 2025, with results expected in 2026.</p><p>Should the final results be positive, the UK National Screening Committee (UK NSC) may consider the use of the test in a national screening programme. A UK NSC-recommended national screening programme would need to consider the effectiveness of the test, balancing the risk of false positives and unnecessary invasive treatments, against potential early detection.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/03/2024 15:09:07 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1693749

	registered interest
	date	05/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Osteoporosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many over 25s have been diagnosed with osteoporosis in the last three years.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	17094
	answer	answer is ministerial correction date of answer 12/03/2024 answer text <p>The information is not collected in the format requested. However, the below table shows the number of finished admission episodes (FAEs) with a primary diagnosis of osteoporosis, for patients aged 25 years old and over in England, for the years 2020/21 to 2022/23:</p><table><tbody><tr><td><p>Year</p></td><td><p>FAEs</p></td></tr><tr><td><p>2020/21</p></td><td><p>32,552</p></td></tr><tr><td><p>2021/22</p></td><td><p>43,391</p></td></tr><tr><td><p>2022/23</p></td><td><p>47,015</p></td></tr></tbody></table><p>Source: Hospital Episode Statistics from NHS England.</p><p>Note: This data provides a proxy to show overall trends.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 12/03/2024 17:51:25 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon

1693013

	registered interest
	date	01/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure equality in bowel cancer outcomes.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	16467
	answer	answer is ministerial correction date of answer 07/03/2024 answer text <p>The National Health Service is taking several steps to improve bowel cancer outcomes for patients across England. The NHS is working towards its Long Term Plan’s ambition of diagnosing 75% of all stageable cancers at stage one and two, by 2028. Achieving this will mean that an additional 55,000 people each year will survive their cancer for at least five years after diagnosis.  With progress made on reducing waiting times, cancer is being diagnosed at an earlier stage more often, with survival rates improving across almost all types of cancer.</p><p> </p><p>In 2023, NHS England’s Help Us Help You campaign urged people to take up the offer of bowel screening when invited, while gradually extending the screening offer from those aged 60 down to 50 years old, ensuring more people are diagnosed with bowel cancer at the earliest stage.</p><p> </p><p>The NHS is also now offering routine preventative bowel cancer screening to thousands of people in England with a genetic condition, Lynch syndrome, that increases their chance of developing bowel cancer and certain other cancers. This gives the NHS a better chance of finding cancers at a time when they can be more easily and effectively treated.</p><p> </p><p>Tackling disparities is important in improving all types of cancer outcomes. The Government is committed to its levelling up mission, to narrow the gap in healthy life expectancy by 2030 and increase healthy life expectancy by five years by 2035. Our approach will continue to focus on supporting people to live healthier lives, helping the NHS and social care provide the best treatment and care for patients, and tackling health disparities through national and system interventions such as the NHS’s Core20PLUS5 programme.</p><p> </p><p>The Office for Health Improvement and Disparities was set up to address health inequalities with a range of interventions, including accelerating prevention programmes, reducing digital exclusion, supporting general practice in deprived communities, and improving health literacy.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 07/03/2024 13:58:23 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4131 label Biography information for Jim Shannon